Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



JPMorgan Healthcare Conference Highlights: Bristol-Myers Squibb

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The JPMorgan Healthcare Conference currently under way in San Francisco is arguably the most important event of the entire year for the health care sector. This is one of the rarest opportunities for biotechnology, pharmaceutical, and medical device companies to open up about where they've been and where they're headed, so it pays to take notice.

One company in particular that I had my eyes on was big pharma Bristol-Myers Squibb (NYSE: BMY  ) . Following the massive failure of BMS-986094 -- the hepatitis-C compound acquired when it purchased Inhibitex for $2.5 billion last January that was discontinued due to safety concerns -- I was very interested in what CEO Lamberto Andreotti had to say about the future of his company. To say I'm disappointed with what this worst CEO of 2012 nominee had to say yesterday might be an understatement.

What's comical is that it only took Andreotti three sentences before the excuses began to fly -- in this case that a cold was going to potentially cut short his presentation.

All kidding aside, Bristol's focus is clearly on distancing itself from blood thinner Plavix, which lost patent protection in May and had been a $5-billion-per-year drug, and to focus on its recently approved drugs including life-changing blood thinner Eliquis, which it developed with Pfizer (NYSE: PFE  ) , and its SGLT-2 inihibitor for Type 2 diabetes, Forxiga, which it developed with AstraZeneca (NYSE: AZN  ) .

Andreotti hit on the key point that in less than two months Eliquis was approved to treat atrial fibrillation in Canada, Europe, Japan, and the United States. As I noted in recent weeks, Eliquis has serious blockbuster potential considering that it mopped the floor with warfarin in every side-by-side comparison, including efficacy and safety.

Bristol may not be as lucky when it comes to Forxiga, which was recently approved in Europe. Although it's the first inhibitor of its kind to gain approval for type 2 diabetes, there are numerous competitors waiting in the wings with stellar results. Johnson & Johnson (NYSE: JNJ  ) subsidiary Janssen Pharmaceuticals is bringing its SGLT-2 inhibitor, Invokana, before the FDA panel later this week. In trial results, Invokana was more effective than placebo in reducing A1C levels after 18 weeks, and, as the Fool's biotech guru Brian Orelli noted, it cleaned up in a head-to-head trial versus Merck's (NYSE: MRK  ) Januvia.

Beyond these two drugs, I expected to hear a lot about what's coming down the pipeline for Bristol. Instead, we received a little information about the company's focus on its immuno-oncology line of drugs, but were largely left out in the cold on how Bristol intends to generate meaningful growth.

Within the immuno-oncology segment, Andreotti focused his attention on FDA-approved metastatic melanoma drug Yervoy and late-stage candidates Nivolumab and Elotuzumab. With respect to Yervoy, Bristol intends to focus its efforts on additional indications for the drug over the next few years. For Nivolumab, which is being tested in phase 3 trials for lung and renal cancer, as well as melanoma, and Elotuzumab, which is also in phase 3 trials for multiple myeloma, Andreotti merely glazed over their potential.

To summarize, it appears that Bristol is going to focus on promoting its newer drugs Eliquis and Forxiga and cross its fingers that the drugs launch well, while also continuing to exert its power within the diabetes space. I'm still not 100% sold on Bristol and AstraZeneca's $5.3 billion purchase of Amylin to get a hold of its diabetes line, and Bristol's "string of pearls" acquisition strategy has largely been a dud thus far. Aside from the expectation of a higher dividend payout in 2013, I'd call this presentation a dud as well.

What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2186914, ~/Articles/ArticleHandler.aspx, 9/30/2016 1:12:08 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,325.00 181.55 1.00%
S&P 500 2,169.69 18.56 0.86%
NASD 5,316.37 47.21 0.90%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 12:56 PM
AZN $33.03 Down -0.02 -0.06%
AstraZeneca CAPS Rating: ****
BMY $54.05 Up +0.18 +0.33%
Bristol-Myers Squi… CAPS Rating: ****
PFE $33.99 Up +0.67 +2.01%
Pfizer CAPS Rating: ****
JNJ $118.35 Up +1.08 +0.92%
Johnson and Johnso… CAPS Rating: *****
MRK $62.43 Up +0.52 +0.84%
Merck and Co. CAPS Rating: ****